Jade Biosciences, Inc. Overview
JBIO market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
JBIO price chart · 1M
- O
- 14.01
- H
- 15.11
- L
- 14.01
- C
- 15.07
- Vol
- 34,898.00
Daily history from Jun 30, 2021
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $14.01
- Previous Close
- $14.09
- Day High
- $15.11
- Day Low
- $14.01
- 52 Week High
- $27.71
- 52 Week Low
- $8.79
- 7 Day Return
- +7.18%
- 30 Day Return
- +9.36%
- 90 Day Return
- -30.68%
- 1 Year Return
- +69.42%
- Daily Notional Volume
- $525.9K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.80 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.36 – $28.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- $50.12 Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $958.4M · P/B 2.13.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
9 captured